Infections from the drug-resistant fungus Candida auris are rising alarmingly in U.S. hospitals, posing a significant risk to already sick patients. Despite being manageable for healthy individuals, its resistance to treatments makes it a growing concern in healthcare settings.
In a surprising turn, the Trump administration is contemplating cuts to H.I.V. prevention efforts that previously saw significant success. What does this mean for public health?
